Evaluation of fibrinogen deficiency
Measuring fibrinogen in patients with elevated plasma levels of fibrin degradation products, patients receiving heparin, and in patients with antibodies to thrombin (following surgical use of topical bovine thrombin)
Identifying afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia when ordered in combination with fibrinogen activity (FIBTP / Fibrinogen, Plasma)
Immunoturbidimetric
FIBAG
Fibrinogen protein
Fibrinogen mass
Fibrinogen concentration
Plasma Na Cit
Supplies: Sarstedt Aliquot Tube 5 mL (T914)
Collection Container/Tube: Light-blue top (3.2% sodium citrate at 9:1 ratio)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot plasma into plastic vial. Send refrigerated.
0.5 mL
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Plasma Na Cit | Refrigerated (preferred) | 14 days | |
Frozen | 30 days | ||
Ambient | 72 hours |
Evaluation of fibrinogen deficiency
Measuring fibrinogen in patients with elevated plasma levels of fibrin degradation products, patients receiving heparin, and in patients with antibodies to thrombin (following surgical use of topical bovine thrombin)
Identifying afibrinogenemia, hypofibrinogenemia, and dysfibrinogenemia when ordered in combination with fibrinogen activity (FIBTP / Fibrinogen, Plasma)
Fibrinogen (clotting factor I) is an essential protein responsible for blood clot formation. In the final step of the coagulation cascade, thrombin converts soluble fibrinogen into insoluble fibrin strands that crosslink and form a clot.
Fibrinogen is synthesized in the liver and has a biological half-life of 3 to 5 days in the circulating plasma. Fibrinogen deficiencies can be congenital or acquired and lead to prolonged coagulation times. Isolated fibrinogen deficiency is an extremely rare inherited coagulation disorder.
Acquired fibrinogen deficiency is most commonly caused by, acute or decompensated intravascular coagulation and fibrinolysis. Other causes of fibrinogen deficiency include advanced liver disease, L-asparaginase therapy, or fibrinolytic agents (eg, streptokinase, urokinase, tissue plasminogen activator).
> or =18 years: 196-441 mg/dL
Reference values have not been established for patients that are less than 18 years of age.
This method measures the total amount of fibrinogen protein (ie, fibrinogen antigen) present in the plasma.
Adequate fibrinogen antigen levels in a context of low fibrinogen activity suggests a dysfibrinogenemia.
Fibrinogen antigen levels lower than 100 mg/dL are associated with an increased risk of bleeding.
Differentiation of congenital from acquired defects of fibrinogen requires clinical correlation and the results of standard clotting-based fibrinogen activity (FIBTP / Fibrinogen, Plasma) testing.
Fibrinogen is an acute phase reactant; plasma levels can be increased by inflammatory illnesses, nephrotic syndrome, liver disease, pregnancy, estrogen therapy, and/or compensated intravascular coagulation.
1. de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013;39(6):585-595
2. Mackie I, Casini A, Pieters M, Purthi R, Reilly-Stitt C, Suzuki A. International council for standardisation in haematology recommendations on fibrinogen assays, thrombin clotting time and related tests in the investigation of bleeding disorders. Int J Lab Hematol. 2024;46(1): 20-32. doi:10.1111/ijlh.14201
The K-ASSAY Fibrinogen test analyzes the quantitative determination of fibrinogen in human plasma by immunoturbidimetric analysis. Samples and antibody reagent are automatically pipetted into individual cuvettes. Following an initial incubation and measurement of sample blank, antiserum is added to the cuvettes. The sample (antigen) solution and antiserum are then mixed in the reaction cuvettes. Insoluble antigen-antibody complexes form. The immune complexes cause an increase in light scattering, which correlates with the concentration of plasma fibrinogen. The absorbance of the solution is measured.(Package insert: K-ASSAY Fibrinogen. Kamiya Biomedical Company; 03/2023)
Monday through Friday
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
85385
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
FIBAG | Fibrinogen Antigen, P | 3256-5 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
FIBAG | Fibrinogen Antigen, P | 3256-5 |